https://pharminent.com/bayers-hyrnuo-wins-accelerated-frontline-approval-in-her2-mutant-nsclc-seven-months-behind-boehringer/ 2026-09-10T20:00:29Z Pharminent en Bayer's Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer 2026-09-10T20:00:26Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-10-2026/ 2026-09-10T17:08:21Z Pharminent en Strategic News Watch • September 10, 2026 2026-09-10T17:08:18Z Blog https://pharminent.com/bayers-hyrnuo-set-for-the-nsclc-frontlines-on-accelerated-fda-label-expansion/ 2026-09-10T18:48:48Z Pharminent en Bayer's Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion 2026-09-10T10:26:07Z Blog https://pharminent.com/hhs-appoints-permanent-fda-cber-cder-heads/ 2026-09-10T15:01:38Z Pharminent en HHS appoints permanent FDA CBER, CDER heads 2026-09-10T09:40:49Z Blog https://pharminent.com/solstice-oncology-secures-225m-to-drive-porustobarts-development-for-cancer-2/ 2026-09-10T18:16:39Z Pharminent en Solstice Oncology secures $225m to drive porustobart's development for cancer 2026-09-10T09:39:18Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-september-9-2026/ 2026-09-09T20:54:18Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • September 9, 2026 2026-09-09T20:54:16Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-september-9-2026/ 2026-09-09T20:52:19Z Pharminent en Manufacturing Intelligence • Weekly Digest • September 9, 2026 2026-09-09T20:52:17Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-8-2026/ 2026-09-09T20:50:58Z Pharminent en Oncology Intelligence Digest • September 8, 2026 2026-09-09T20:50:56Z Blog https://pharminent.com/fda-names-permanent-cder-and-cber-directors-while-the-commissioners-post-awaits-confirmation/ 2026-09-09T19:48:36Z Pharminent en FDA Names Permanent CDER and CBER Directors While the Commissioner's Post Awaits Confirmation 2026-09-09T19:48:32Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-9-2026/ 2026-09-09T17:41:23Z Pharminent en Strategic News Watch • September 9, 2026 2026-09-09T17:41:21Z Blog https://pharminent.com/sandoz-plans-vast-and-vertically-integrated-supply-chain-to-support-100-biosimilar-vision/ 2026-09-10T18:17:18Z Pharminent en Sandoz plans 'vast and vertically integrated' supply chain to support 100-biosimilar vision 2026-09-09T13:00:53Z Blog https://pharminent.com/novartiss-del-desiran-misses-primary-endpoint-in-harbor-putting-the-12b-avidity-deal-under-scrutiny/ 2026-09-08T20:56:52Z Pharminent en Novartis's Del-Desiran Misses Primary Endpoint in HARBOR, Putting the $12B Avidity Deal Under Scrutiny 2026-09-08T20:09:35Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-8-2026/ 2026-09-08T19:07:19Z Pharminent en Strategic News Watch • September 8, 2026 2026-09-08T16:45:55Z Blog